MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Bullish option flow detected in Pfizer (PFE) with 70,941 calls trading, 1.3x expected, and implied vol increasing over 1 point to 23.18%.

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Revenue from COVID vaccine Comirnaty brought in sales of $3.38 billion, while antiviral treatment Paxlovid was $727 million ...

“They are becoming vaccine-hesitant.” Pfizer, Moderna and Novavax — the makers of Covid vaccines used in the U.S. — would likely sue HHS if Kennedy were to revoke the declaration. Children ...

U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

Biotechnology company Moderna (NASDAQ:MRNA) gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim as a ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...